Any current/future new fundraising through debt or equity?

There is no expectation for significant new fundraising through debt or equity in the near term. The company has already made a substantial capex investment last year, creating infrastructure to handle production capacity up to 60-70 million devices annually. Additional capex of $15-20 million may be needed to scale from 25-30 million to 70 million devices, but this is planned over the next 6-7 years, not the next 2-3 years. The management does not foresee the need for large-scale fundraising (e.g., $50-100 million) for semaglutide or other programs. The focus is on improving capacity utilizat

Any current/future capex/capital investment/strategic investment?

No substantial capex is planned immediately; only small capexes are expected in FY25. Focus currently is on improving utilization of existing capacity rather than large new investments. A previous large capex was done last year to create infrastructure supporting up to 60-70 million devices annually. Installed equipment currently supports 25-30 million devices per year; additional machinery will be added as approvals and scale-up occur. Future additional capex of around $15-20 million may be required to expand capacity from 30 million to 70 million devices, but this is not expected within the

Future growth expectations in sales/revenue/volumes?

Pharma segment expected to grow at 50%-60% in the current year (FY '25). Overall volume of pens/devices anticipated to increase from ~11 million in FY '24 to around 17-18 million in FY '25, reflecting 15%-16% growth. Capacity utilization currently around 40%, expected to increase as new business scales up. Plans to ramp up pen/device volumes gradually with approvals on proprietary platforms like Teriparatide and Liraglutide anticipated in FY '25. Additional capex of $15-$20 million planned over the next 6-7 years to expand capacity from current 25-30 million devices per year to ~60-70

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects margin improvement over the next 2-3 years driven by higher pharma revenues and more value-added products (Page 9). EBITDA margin improved to 19.2% in FY24, up 350 basis points YoY; PAT margin improved 310 basis points to 8.9% (Page 4). Pharma segment revenue grew 87% in FY24, signaling strong growth potential (Page 4). Capacity utilization currently at 40%, expected to increase in coming years, supporting volume growth (Page 4, 16). Healthcare/pharma segment expected to grow 50%-60% in the current year (Page 8-9). Pen volumes to grow at 15%-16% annually, with potential inc

Current/ Expected Orderbook/ Pending Orders?

Total ongoing projects across all molecules: approximately 20 to 23. Added 7 confirmed contracts in the recent year (4 earlier plus 3 more in Q4). Focus on regulated markets with approvals expected, particularly for Teriparatide and Liraglutide pens. Expecting commercial supplies for Teriparatide and Liraglutide pens in the current year. Auto-injector projects account for 4 out of the total projects; remainder are pen injectors. Pipeline for new contracts remains strong with ongoing bidding for new business. Capacity utilization currently ~40%, expected to increase as new business ramps up. Ex

Shaily Engineer.Q4 FY24Consumer Durables

Shaily Engineer. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,009P/E: 81.3Market Cap: ₹14.5K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Pharma segment expected to grow at 50%-60% in the current year (FY '25).
Overall volume of pens/devices anticipated to increase from ~11 million in FY '24 to around 17-18 million in FY '25, reflecting 15%-16% growth.
Capacity utilization currently around 40%, expected to increase as new business scales up.
Plans to ramp up pen/device volumes gradually with approvals on proprietary platforms like Teriparatide and Liraglutide anticipated in FY '25.
Additional capex of $15-$20 million planned over the next 6-7 years to expand capacity from current 25-30 million devices per year to ~60-70 million.
Revenue growth expected from increasing proportion of proprietary devices (currently shifting from 10% to ~30-40% of value).
Consumer segment faced a degrowth of ~4% due to raw material pass-through and lower toy sales but base business expected to grow 12%-15%.
Shaily UK revenue to be back-ended with more growth expected in H2 FY '25.

Margin guidance

Category 3

The company expects margin improvement over the next 2-3 years driven by higher pharma revenues and more value-added products (Page 9).
EBITDA margin improved to 19.2% in FY24, up 350 basis points YoY; PAT margin improved 310 basis points to 8.9% (Page 4).
Pharma segment revenue grew 87% in FY24, signaling strong growth potential (Page 4).
Capacity utilization currently at 40%, expected to increase in coming years, supporting volume growth (Page 4, 16).
Healthcare/pharma segment expected to grow 50%-60% in the current year (Page 8-9).
Pen volumes to grow at 15%-16% annually, with potential increase from 11-12 million devices to 17-18 million in FY25 (Page 14).
No substantial capex planned next 2-3 years; expansion will be via better utilization and incremental investments (Page 9, 16).
EBITDA margin reported around 20%-21% consistently in recent quarters with expectations to improve gradually (Page 9).

See what Shaily Engineer. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no expectation for significant new fundraising through debt or equity in the near term.
The company has already made a substantial capex investment last year, creating infrastructure to handle production capacity up to 60-70 million devices annually.
Additional capex of $15-20 million may be needed to scale from 25-30 million to 70 million devices, but this is planned over the next 6-7 years, not the next 2-3 years.
The management does not foresee the need for large-scale fundraising (e.g., $50-100 million) for semaglutide or other programs.
The focus is on improving capacity utilization and organic growth rather than immediate capital raising.
No substantial capex or capital raising is planned for FY25; only minor capex will be undertaken to improve utilization.

Order book

Yes

Total ongoing projects across all molecules: approximately 20 to 23.
Added 7 confirmed contracts in the recent year (4 earlier plus 3 more in Q4).
Focus on regulated markets with approvals expected, particularly for Teriparatide and Liraglutide pens.
Expecting commercial supplies for Teriparatide and Liraglutide pens in the current year.
Auto-injector projects account for 4 out of the total projects; remainder are pen injectors.
Pipeline for new contracts remains strong with ongoing bidding for new business.
Capacity utilization currently ~40%, expected to increase as new business ramps up.
Expansion in contract manufacturing, including specialized devices and dry powder inhalers, mainly insulin pens.
Total device volumes expected to grow from 11 million in FY '24 to 17-18 million in FY '25 with ~15-16% growth.

See what Shaily Engineer. management said on order book — free account, 30 seconds.

Capex plans

Yes

No substantial capex is planned immediately; only small capexes are expected in FY25.
Focus currently is on improving utilization of existing capacity rather than large new investments.
A previous large capex was done last year to create infrastructure supporting up to 60-70 million devices annually.
Installed equipment currently supports 25-30 million devices per year; additional machinery will be added as approvals and scale-up occur.
Future additional capex of around $15-20 million may be required to expand capacity from 30 million to 70 million devices, but this is not expected within the next 2-3 years; envisioned over 6-7 years.
Capex for semaglutide-related scale-up is expected to be lower due to location in India and existing infrastructure.
The company is managing growth and capacity expansion prudently without aggressive capital investment in the near term.

Track Shaily Engineer. — get its next earnings analysis in your feed

How does Shaily Engineer. rank vs peers in Consumer Durables?

Pro feature

ThisShaily Engineer.

Rev 3Mar 3

See where Shaily Engineer. sits in Consumer DurablesSee which companies these are, and every other name in the sector.Open rankings

How does Shaily Engineer. rank in Consumer Durables?

Compare Shaily Engineer. against every Consumer Durables company (Q4 FY24) on revenue, margins and earnings-call signals.

View Consumer Durables leaderboard →

What Shaily Engineer.'s management said in earlier quarters

Others in Consumer Durables this season

Khadim India Ltd (Q1 FY27)
Revenue from Operations for Q1 FY27 stood at ₹778.4 Mn, down by -18.7% YoY (Page 17, 15). Key investor presentation takeaways from Khadim India Ltd's Q1 FY27 in
Duroply Industries Ltd (Q1 FY27)
Year-on-year (YoY) revenue growth: 6.49% (Q1 FY27 vs Q1 FY26) . Key investor presentation takeaways from Duroply Industries Ltd's Q1 FY27 investor presentation
Deepa Jewellers Ltd (Q1 FY27)
Q1-FY27 Revenue from Operations: INR 4,311 Mn, up 39.0% YoY from INR 3,101 Mn in Q1-FY26 (Page 13, 11) . Key investor presentation takeaways from Deepa Jeweller
Priority Jewels Ltd (Q1 FY27)
Revenue from Operations for 3 months ended June 30, 2026 (3M27): ₹1,250 million (page 18). Key investor presentation takeaways from Priority Jewels Ltd's Q1 FY2

Compare:vs Titan Company Ltd vs Asian Paints vs LG Electronics

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shaily Engineer. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Shaily Engineer. rank in Consumer Durables?

Continue your research

What Shaily Engineer.'s management said in earlier quarters

Others in Consumer Durables this season